Laboratory Corp. of America Holdings
Laboratory Corp. of America Holdings (LabCorp, ticker LH) is a large clinical diagnostics and healthcare services company providing laboratory testing, diagnostic information, and drug development services to hospitals, physicians and biopharma clients. With a market capitalisation of about $23.6bn, LabCorp earns revenue from fee-for-service testing, contracts with healthcare providers, and outsourced clinical trial services. Key investor considerations include steady structural demand for diagnostics from an ageing population and growing use of personalised medicine, balanced against sensitivity to reimbursement rates, regulatory change and competition. LabCorp’s results can be cyclical—volumes often fluctuate with public-health trends such as respiratory outbreaks—and capital allocation choices and acquisitions affect near-term profitability. Investors should review recent financials, margins, cash flow and valuation, and consider exposure to healthcare reimbursement risk. This information is educational only and not personal financial advice; investors should assess suitability and consult a professional before acting.
Why It's Moving
Labcorp Bolsters Oncology Edge with Fresh Diagnostics Momentum and Board Boost Ahead of Dividend Payout.
Labcorp continues riding high on recent oncology innovations like new clinical evidence for its Plasma Detect test and an AI-powered pathology collaboration with Lunit, signaling deeper penetration into precision cancer care. Investors eye the imminent board addition of pharma veteran Victor Bulto effective December 1, alongside a $0.72 quarterly dividend payable December 11, underscoring steady execution amid diagnostics growth.
- Peer-reviewed studies validate Plasma Detect's role in molecular residual disease monitoring, positioning Labcorp to capture rising demand for advanced cancer tracking solutions.
- New partnership with Lunit integrates AI and digital pathology for oncology research, enhancing Labcorp's tech-driven diagnostics portfolio and operational efficiencies.
- Victor Bulto's board appointment brings global pharma expertise, while the upcoming dividend reinforces shareholder commitment in a strong Q3 earnings aftermath.
Labcorp Bolsters Oncology Edge with Fresh Diagnostics Momentum and Board Boost Ahead of Dividend Payout.
Labcorp continues riding high on recent oncology innovations like new clinical evidence for its Plasma Detect test and an AI-powered pathology collaboration with Lunit, signaling deeper penetration into precision cancer care. Investors eye the imminent board addition of pharma veteran Victor Bulto effective December 1, alongside a $0.72 quarterly dividend payable December 11, underscoring steady execution amid diagnostics growth.
- Peer-reviewed studies validate Plasma Detect's role in molecular residual disease monitoring, positioning Labcorp to capture rising demand for advanced cancer tracking solutions.
- New partnership with Lunit integrates AI and digital pathology for oncology research, enhancing Labcorp's tech-driven diagnostics portfolio and operational efficiencies.
- Victor Bulto's board appointment brings global pharma expertise, while the upcoming dividend reinforces shareholder commitment in a strong Q3 earnings aftermath.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Laboratory Corp. of America stock, expecting it to increase in value.
Financial Health
Laboratory Corp. is performing well financially, showing good revenue, profits, and cash flow.
Dividend
Laboratory Corp. of America Holdings has a low dividend yield of 1.08%, which may not be appealing for dividend-focused investors. If you invested $1000 you would be paid $10.80 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring LH
Riding The Regulatory Wave In Healthcare
The Department of Justice's investigation into UnitedHealth's Medicare billing practices has cast a shadow over the health insurance industry, potentially leading to stricter oversight. This creates an investment opportunity in companies that provide compliance and auditing services, which are essential for navigating a more complex regulatory environment.
Published: July 25, 2025
Explore BasketDiagnostic Takeover Targets
This carefully selected group of stocks features innovative diagnostic companies that could become acquisition targets following recent takeover interest in the sector. Professional analysts have identified these companies for their unique technologies and established market positions in a consolidating healthcare landscape.
Published: July 15, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Diagnostics demand trends
Ageing populations and personalised medicine support long-term demand for testing, though volumes can fluctuate with public-health events and policy changes.
Global service footprint
A broad geographic presence and biopharma contracts diversify revenue, but differing regulations and reimbursement rules across markets add complexity.
Innovation and services
Investments in technology and clinical-trial services may improve margins over time, although competition and pricing pressure can constrain gains.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Chemed Corp.
Provides hospice and palliative care services to patients facing life-limiting illness
Alignment Healthcare, Inc.
Alignment Healthcare, Inc. is a consumer-centric platform designed to improve the healthcare experience for seniors. The Company’s operations primarily consist of Medicare Advantage Plans in the states of California, North Carolina, Nevada, Arizona, Florida and Texas. It partners with local providers to deliver coordinated care, powered by its customized care model, 24/7 concierge care team and purpose-built technology (AVA). AVA’s capabilities include consumer experience, internal care delivery, external providers, health plan operations and growth operations. AVA offers a digital ecosystem that enables its members and their support system to get the information and care they need, when and how they need it. With their AVA-powered member portal and mobile app, seniors have many self-service capabilities and can get 24/7 care, send secure messages to their concierge and care teams, check their rewards and ACCESS On-Demand Concierge Card balance, and view their health history.
Brookdale Senior Living Inc.
A leading owner and operator of senior living communities in the United States.
